Journal of Vaccines & Vaccination

Department of Clinical Research, Narayana Health, Bangalore, India

Biography

Alben Sigamani is currently working as a Professor in the Department of Clinical Research. His research interests includes Medicine. He is serving as an editorial member and reviewer of several international reputed journals. He has successfully completed his Administrative responsibilities. He has authored of many research articles/books related to Medicine.

Publications

• Research Article   
  Galectin Antagonist use in Mild Cases of SARS-CoV-2: Pilot Feasibility Randomised, Open Label, Controlled Trial
  Author(s): Alben Sigamani*, Mathu Ruthra, Sudhishma, Samarth Shetty, Madhavi, Anup Chugani, Hana Chen-Walden, David Platt and Thomas Kutty
  
  Importance: Novel SARS-CoV-2 virus has infected nearly 100 million people across the world and is highly contagious. There is a need for a novel mechanism to block viral entry and stop its replication. Background: Spike protein N Terminal Domain (NTD) of the novel SARS-CoV-2 is essential for viral entry and replication in human cell. Thus the S1 NTD of human coronavirus family, which is similar to a galectin binding site-human galactose binding lectins, is a potential novel target for early treatment in COVID-19. Objectives: To study the feasibility of performing a definitive trial of using galectin antagonist–Prolectin-M as treatment for mild, symptomatic, rRT-PCR positive, COVID-19. Main outcomes and measures: Cycle threshold (Ct) value is number of cycles needed to express.. View more»
  

  DOI: 10.35248/2157-7560.21.S10.003

  Abstract HTML PDF